Orion Announces Positive Phase III Results for Nubeqa in Prostate Cancer

Orion Corporation reported positive Phase III clinical results for its drug Nubeqa (darolutamide), showing a 58% reduction in the risk of metastasis or death when combined with androgen deprivation therapy and radiation in high-risk prostate cancer patients. The data was presented at the ESMO 2026 congress, underscoring Nubeqa's efficacy in this patient population and strengthening its position in Orion's oncology portfolio.